no small cell lung cancer
Conditions
Interventions
Test group:Local consolidation therapy combined with immunochemotherapy
Control group:first-line immunochemotherapy
Sponsors
Yueyang Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age>=18 years old; At the first visit, the pathological diagnosis was NSCLC (squamous cell carcinoma or adenocarcinoma, excluding other types of NSCLC), and the driver gene (EGFR/ALK) was negative; According to the 9th edition of the UICC TNM classification criteria, the stage is TxNxM1 (stage IV) (systematic evaluation methods include CT/MRI and/or PET-CT); 4. Immunochemotherapy is used as the initial treatment; 5. After first-line immunotherapy (21 days/cycle, a total of 3 cycles), if the ORD criteria (metastatic lesions=90 g/L (no blood transfusion within 14 days); Ii. Neutrophil count>1.5 × 10 ^ 9/L; iii Platelet count>=100 × 10 ^ 9/L; b) Biochemical examination: i. Total bilirubin=60ml/min (Cockcroft Gault formula); c) Cardiac Doppler ultrasound evaluation: Left ventricular ejection fraction (LVEF)>=50%; d) Blood glucose should be controlled at fasting blood glucose<7.2 mmol/L, non fasting blood glucose<10 mmol/L, and glycated hemoglobin<7%. 8. Sign the informed consent form; 9. Good compliance, family members agree to cooperate in receiving survival follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with abnormal coagulation function and bleeding tendency (must meet the requirement of INR being within the normal range without using anticoagulants within 14 days before randomization); Patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogues; Under the premise that the international normalized ratio (INR) of prothrombin time is less than 1.5, it is allowed to use low-dose warfarin (1mg orally, once daily) or low-dose aspirin (daily dose not exceeding 100 mg) for preventive purposes; 2. Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders; 3. Screening for arterial/venous thrombosis events that have occurred within the previous 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis (excluding those caused by venous catheterization during previous chemotherapy and judged to have recovered by researchers), and pulmonary embolism; 4. Contraindications for immunotherapy, radiotherapy, and puncture; 5. According to the researcher's judgment, there are accompanying diseases that seriously endanger patient safety or affect the completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival (PFS);time to progression(TTP); | — |
Countries
China
Contacts
Public ContactXie Wangti
Yueyang Central Hospital
Outcome results
None listed